Cancer Metabolism Based Therapeutics Market Analysis and In-depth Research on Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/961

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

Calithera Biosciences, Inc. announced novel cancer therapeutic drug named CB–839 in 2017. The FDA granted CB-839 as a Fast Track designation drug with the combination of everolimus for the treatment of metastatic renal cell carcinoma. CB-839 is being evaluated in clinical trials phase I and II for the treatment of solid tumors non-small cell lung cancer, renal cell carcinoma, melanoma, and triple negative breast cancer.

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, approximately 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths were occurred in 2014.

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/961

Global Cancer Metabolism Based Therapeutics Market Taxonomy

On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories

By Drug –

CPI-613
Enasidenib
By Indication –

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Metastatic Renal Cell Carcinoma
Melanoma
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.